8-K: cbdMD Faces Delisting Risk After Failing to Meet NYSE American Equity Standard

cbdMD, Inc. has received a notice from the NYSE American for non-compliance with continued listing standards due to insufficient stockholders' equity.

Summary

• cbdMD, Inc. received a notification from the NYSE American on December 31, 2024, stating the company is not in compliance with the continued listing standard requiring stockholders' equity of $2 million or more.
• This non-compliance is due to the company reporting stockholders' equity of $1,963,417 as of September 30, 2024, and losses in four of the last five fiscal years.
• The company is already under a compliance plan accepted on August 20, 2024, for having stockholders' equity under $4 million, with a deadline of December 5, 2025, to regain compliance.
• The company is exploring options to increase its equity, including converting its Series A Preferred Stock and accrued dividends, totaling $4.67 million as of September 30, 2024, into common stock.
• Failure to meet the listing standards by December 5, 2025, or make sufficient progress could lead to delisting.
• The notice does not immediately affect the trading of the company's common stock (YCBD) and preferred stock (YCBD-PA), but they will be marked with '.BC' to indicate non-compliance.
• The company reduced cash consumption from $4.9 million in fiscal 2023 to approximately $0.7 million in fiscal 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges and a potential delisting, which is a negative signal for investors. While the company is taking steps to address the issues, the uncertainty and risks outweigh the positives.

Positives

• The company's common and preferred stock will continue to trade on the NYSE American during the compliance period.
• The company has significantly reduced cash consumption from $4.9 million in fiscal 2023 to approximately $0.7 million in fiscal 2024.
• The company is actively exploring options to regain compliance, including a potential conversion of preferred stock to common stock.

Negatives

• The company is not in compliance with the NYSE American's continued listing standards due to insufficient stockholders' equity.
• The company has reported losses in four of the last five fiscal years.
• There is no guarantee that the company will be able to regain compliance within the required timeframe.
• Delisting could negatively impact the company's stock liquidity, market price, and ability to raise capital.
• Delisting could trigger an event of default under the company's outstanding Senior Secured Convertible Promissory Notes.

Risks

• Failure to regain compliance with NYSE American listing standards by December 5, 2025, could lead to delisting.
• Delisting could reduce the liquidity and market price of the company's stock.
• Delisting could limit the company's ability to raise equity financing.
• Delisting could trigger an event of default under the company's outstanding Senior Secured Convertible Promissory Notes.
• There is no assurance that the company will be able to achieve compliance with the NYSE American's continued listing standards within the required timeframe.

Future Outlook

The company is focused on achieving positive net income and is committed to undertaking transactions to achieve compliance with NYSE American requirements, including seeking shareholder approval to convert preferred stock and accrued dividends into common stock. However, there is no assurance that the company will be able to achieve compliance within the required timeframe.

Management Comments

• The company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE Americans requirements.
• The company is focused on achieving positive net income.

Industry Context

The CBD industry is facing increasing regulatory scrutiny and competition, which may be contributing to the financial challenges faced by cbdMD. The company's focus on reducing cash consumption and exploring options to increase equity are common strategies for companies in this sector facing financial difficulties.

Comparison to Industry Standards

• Many smaller CBD companies are facing similar challenges with profitability and maintaining listing requirements.
• Companies like Charlotte's Web and CV Sciences, while larger, have also faced scrutiny and market volatility.
• The need to raise capital and achieve profitability is a common theme in the CBD industry, especially for companies that went public during the initial hype of the sector.
• The reduction in cash consumption is a positive sign, but the company needs to demonstrate a clear path to profitability and compliance to avoid delisting.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the value of their investment.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers may be concerned about the long-term viability of the company and its brands.
• Creditors face increased risk due to the potential for default on outstanding debt.

Next Steps

• The company will need to submit a plan to the NYSE American to regain compliance.
• The company will seek shareholder approval to convert preferred stock into common stock.
• The company will continue to focus on achieving positive net income.

Key Dates

Keywords

NYSE American, delisting, compliance, stockholders' equity, preferred stock, common stock, listing standards, cbdMD, YCBD, YCBD-PA